Novo Nordisk A/s

Transtech Pharma, Inc.

Schering Aktiengesellschaft

Other

Leo-pharma A/s

Ziylo Limited

Anthony Murray

Jesper F Lau

Lone Jeppesen

Robert Carl Andrews

Dharma Rao Polisetti

Michael Ankersen

Govindan Subramanian

Kalpathy Chidambareswaran Santhosh

Per Vedso

Marit Kristiansen

Per Vedsø

Daniel Peter Christen

Adnan M M Mjalli

Jeremy T Cooper

Per Sauerberg

Mustafa Guzel

Janos Tibor Kodra

Jane Marie Lundbeck

Peter Faarup

Paw Bloch

Paul Stanley Bury

Maria Carmen Valcarce-Lopez

Jens Breinholt

Thorsten Blume

Ingrid Pettersson

Lise Brown Christiansen

Frederik Christian Gronvald

János Tibor Kodra

Per Vedsoe

Niels Blume

Christian Grondahl

Jan Lund Ottesen

Maria Carmen Valcarce Lopez

Peter Madsen

Thomas Kruse

Thomas Hoeg-Jensen

Bapu Reddy Gaddam

Erik Rytter Ottosen

Daniel Rodriguez Greve

Simon Feldbæk Nielsen

Gunnar Grue-Sørensen

Mathias Norrman

Susanne Hostrup

Christian Fledelius

Anthony Davis

Tine Glendorf

Søren Christian Schou

Claudia Ulrich Hjoerringgaard

Adnan Mm Mjalli

Carsten Ryttersgaard

Andrew Michael Chapman

Alice Ravn Madsen

Tina Dahlerup Poulsen

Martin Muenzel

Lone Jeppsen

Frederick Christian Grønvald

Frederick Christian Gr&oslash;nvald

Santhosh Chidambareswaran Kalpathy

Frederik Christian Grønvald

Claudia Ulrich HJØRRINGGAARD

Martin MÜNZEL

Daniel P Christen

The present invention provides glucose sensitive insulin derivatives comprising a macrocycle, a glucose mimetic and human insulin or an analogue thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such glucose sensitive insulin derivatives, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes.

Glucose sensitive insulins and uses thereof

The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Insulin derivatives and the medical uses hereof

The invention relates to compounds of general formula (I) wherein A, R, R, R, R, R, R, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation. 

Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors

This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Aryl carbonyl derivatives as therapeutic agents

This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Heteroaryl-ureas and their use as glucokinase activators

The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

Urea glucokinase activators

This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.

The present invention relates to N-heteroaryl-benzamides, pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful in diseases or medical conditions mediated by glucokinase.

Benzamide glucokinase activators

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes

This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. 

Dicycloalkylcarbamoyl ureas as glucokinase activators

Growing community of inventors

Hellerup, Denmark

Anthony Murray